SG Americas Securities LLC Purchases 53,795 Shares of Illumina, Inc. $ILMN

SG Americas Securities LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 775.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 60,728 shares of the life sciences company’s stock after purchasing an additional 53,795 shares during the period. SG Americas Securities LLC’s holdings in Illumina were worth $5,767,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. WCM Investment Management LLC increased its holdings in shares of Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after purchasing an additional 247,460 shares during the period. Loomis Sayles & Co. L P grew its position in Illumina by 1.9% during the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares in the last quarter. AQR Capital Management LLC grew its position in Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after buying an additional 1,174,295 shares in the last quarter. Geode Capital Management LLC increased its stake in Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after acquiring an additional 21,342 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Illumina by 51.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after acquiring an additional 667,978 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on ILMN shares. Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday. Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday, October 31st. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Guggenheim upped their target price on shares of Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Finally, Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $122.56.

Insider Activity

In related news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 2.60% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $141.07 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $153.06. The firm’s fifty day moving average is $130.01 and its 200 day moving average is $109.77. The firm has a market cap of $21.56 billion, a P/E ratio of 31.63, a P/E/G ratio of 2.35 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm posted $1.14 earnings per share. The firm’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.